发布求助
文献互助 智能选刊 最新文献

Digestive and Liver Disease Supplements最新文献

筛选
英文 中文
Updates on diagnosis: new tools? How can we measure activity? 诊断的最新进展:新工具?我们如何衡量活动?
Digestive and Liver Disease Supplements Pub Date : 2008-03-01 DOI: 10.1016/S1594-5804(08)60013-3
F. Pallone
{"title":"Updates on diagnosis: new tools? How can we measure activity?","authors":"F. Pallone","doi":"10.1016/S1594-5804(08)60013-3","DOIUrl":"10.1016/S1594-5804(08)60013-3","url":null,"abstract":"","PeriodicalId":100375,"journal":{"name":"Digestive and Liver Disease Supplements","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2008-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1594-5804(08)60013-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84782688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Top down therapy in Crohn's disease 克罗恩病的自上而下疗法
Digestive and Liver Disease Supplements Pub Date : 2008-03-01 DOI: 10.1016/S1594-5804(08)60018-2
S. Ghosh
{"title":"Top down therapy in Crohn's disease","authors":"S. Ghosh","doi":"10.1016/S1594-5804(08)60018-2","DOIUrl":"10.1016/S1594-5804(08)60018-2","url":null,"abstract":"","PeriodicalId":100375,"journal":{"name":"Digestive and Liver Disease Supplements","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2008-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1594-5804(08)60018-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81945765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Opportunistic infections and anti-tumor necrosis factor antagonists in patients with IBD: prevention and diagnosis IBD患者的机会性感染和抗肿瘤坏死因子拮抗剂:预防和诊断
Digestive and Liver Disease Supplements Pub Date : 2008-03-01 DOI: 10.1016/S1594-5804(08)60022-4
J.F. Rahier , J.F. Colombel
{"title":"Opportunistic infections and anti-tumor necrosis factor antagonists in patients with IBD: prevention and diagnosis","authors":"J.F. Rahier , J.F. Colombel","doi":"10.1016/S1594-5804(08)60022-4","DOIUrl":"10.1016/S1594-5804(08)60022-4","url":null,"abstract":"","PeriodicalId":100375,"journal":{"name":"Digestive and Liver Disease Supplements","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2008-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1594-5804(08)60022-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87482196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New developments in biologics therapy: what about from the medical point of view? 生物制剂治疗的新发展:从医学角度看如何?
Digestive and Liver Disease Supplements Pub Date : 2008-03-01 DOI: 10.1016/S1594-5804(08)60023-6
A. Armuzzi, F. De Vincentis, P. Fedeli, A. Gasbarrini
{"title":"New developments in biologics therapy: what about from the medical point of view?","authors":"A. Armuzzi, F. De Vincentis, P. Fedeli, A. Gasbarrini","doi":"10.1016/S1594-5804(08)60023-6","DOIUrl":"10.1016/S1594-5804(08)60023-6","url":null,"abstract":"","PeriodicalId":100375,"journal":{"name":"Digestive and Liver Disease Supplements","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2008-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1594-5804(08)60023-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79619723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Crohn's disease classification and its clinical usefulness 克罗恩病的分类及其临床应用
Digestive and Liver Disease Supplements Pub Date : 2008-03-01 DOI: 10.1016/S1594-5804(08)60012-1
C. Prantera
{"title":"Crohn's disease classification and its clinical usefulness","authors":"C. Prantera","doi":"10.1016/S1594-5804(08)60012-1","DOIUrl":"10.1016/S1594-5804(08)60012-1","url":null,"abstract":"","PeriodicalId":100375,"journal":{"name":"Digestive and Liver Disease Supplements","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2008-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1594-5804(08)60012-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74346941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Crohn's Disease: Achieving Patients' Benefits Paris, 27th October 2007 克罗恩病:实现患者利益，巴黎，2007年10月27日
Digestive and Liver Disease Supplements Pub Date : 2008-03-01 DOI: 10.1016/S1594-5804(08)60011-X
S. Ardizzone , F. Rizzello
{"title":"Crohn's Disease: Achieving Patients' Benefits Paris, 27th October 2007","authors":"S. Ardizzone , F. Rizzello","doi":"10.1016/S1594-5804(08)60011-X","DOIUrl":"10.1016/S1594-5804(08)60011-X","url":null,"abstract":"","PeriodicalId":100375,"journal":{"name":"Digestive and Liver Disease Supplements","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2008-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1594-5804(08)60011-X","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"105164875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of bacterial flora and its products in the functioning of the small intestine 细菌菌群及其产物在小肠功能中的作用
Digestive and Liver Disease Supplements Pub Date : 2007-09-01 DOI: 10.1016/S1594-5804(08)60003-0
G. Gasbarrini , M. Montalto , R. Assisi
{"title":"The role of bacterial flora and its products in the functioning of the small intestine","authors":"G. Gasbarrini ,&nbsp;M. Montalto ,&nbsp;R. Assisi","doi":"10.1016/S1594-5804(08)60003-0","DOIUrl":"10.1016/S1594-5804(08)60003-0","url":null,"abstract":"<div><p>In recent years, particular attention has been paid to the role of the intestinal microflora in the multiple functions of the small intestinal (absorbent, secretory, immunological, endocrine, transport, barrier). The demonstrated beneficial effects of certain bacteria on human health has enabled probiotics antibiotics to be used for therapeutic purposes in a number of gastrointestinal diseases. Certain products of bacterial metabolism (e.g. butyrate) could provide further therapeutic weapons in a sector in which treatment has long proved difficult.</p></div>","PeriodicalId":100375,"journal":{"name":"Digestive and Liver Disease Supplements","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2007-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1594-5804(08)60003-0","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79144393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Butyrate in the treatment of ulcerative colitis 丁酸盐治疗溃疡性结肠炎
Digestive and Liver Disease Supplements Pub Date : 2007-09-01 DOI: 10.1016/S1594-5804(08)60008-X
P. Vernia
{"title":"Butyrate in the treatment of ulcerative colitis","authors":"P. Vernia","doi":"10.1016/S1594-5804(08)60008-X","DOIUrl":"10.1016/S1594-5804(08)60008-X","url":null,"abstract":"<div><p>Butyrate, a substance produced in the colon via bacterial fermentation processes, constitutes an important source of energy for colonic mucosa cells. It also plays an important role in the regulation of intraluminal homeostasis, modulation of inflammation, control of cellular proliferation and differentiation, and repair of mucosal lesions.</p><p>Butyrate has been studied in clinical applications, particularly inflammatory bowel diseases of the colon. While available data are not entirely conclusive, this substance appears to have a useful therapeutic role complementary to that of standard drugs. A body of experimental data also suggests that this short-chain fatty acid may exert preventive action against colorectal cancer, but for the moment this is still a hypothesis that remains to be verified. More generally, butyrate has been shown to be useful in certain types of diarrhoea, particularly chronic forms, by promoting absorption of water and electrolytes.</p></div>","PeriodicalId":100375,"journal":{"name":"Digestive and Liver Disease Supplements","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2007-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1594-5804(08)60008-X","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90622511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 10
Efficacy of butyrate on rectal toxicity of radiotherapy in prostate cancer patients 丁酸盐对前列腺癌放疗患者直肠毒性的影响
Digestive and Liver Disease Supplements Pub Date : 2007-09-01 DOI: 10.1016/S1594-5804(08)60007-8
L.S. Mete, D. Assisi, V. Casale
{"title":"Efficacy of butyrate on rectal toxicity of radiotherapy in prostate cancer patients","authors":"L.S. Mete,&nbsp;D. Assisi,&nbsp;V. Casale","doi":"10.1016/S1594-5804(08)60007-8","DOIUrl":"10.1016/S1594-5804(08)60007-8","url":null,"abstract":"<div><h3>Background</h3><p>Standard treatment with beclomethasone and/or mesalazine in the late actinic proctitis gives poor results. Butyrate constitutes an energy source for colonocytes and deficiency in this substance can result in mucosal hyperplasia as well as acute or chronic inflammation.</p></div><div><h3>Aims</h3><p>To assess the efficacy of oral butyrate in late actinic proctitis in prostate cancer patients.</p></div><div><h3>Materials and methods</h3><p>26 patients were included in the study and treated with oral butyrate in combination with topical mesalazine and/or beclomethasone for 6 months and 44 control subjects received topical therapy with mesalazine and/or beclomethasone for 6 months. Both groups underwent clinical examination as well as pre-treatment (T0) and post-treatment endoscopy (T2).</p></div><div><h3>Results</h3><p>Endoscopic evaluation between T0 and T2 demonstrated improved clinical condition in 50% of patients <em>vs.</em> 20% of controls (<em>p</em> = NS); complete normalisation was seen in 10% of patients but in none of the controls (<em>p</em> = NS). Evaluation of clinical status between T0-T2 showed remission with resolution of symptoms in 60% of patients <em>vs.</em> none of the controls (<em>p</em> &lt; 0.0001).</p></div><div><h3>Conclusions</h3><p>The preliminary results of our study show significantly superior efficacy of therapy in the group receiving butyrate supplement. These findings are encouraging and require confirmation in a larger patient population.</p></div>","PeriodicalId":100375,"journal":{"name":"Digestive and Liver Disease Supplements","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2007-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1594-5804(08)60007-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80823520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Butyric acid: pharmacological aspects and routes of administration 丁酸:药理学方面和给药途径
Digestive and Liver Disease Supplements Pub Date : 2007-09-01 DOI: 10.1016/S1594-5804(08)60004-2
L. Spina , F. Cavallaro , N.I. Fardowza , P. Lagoussis , D. Bona , C. Ciscato , A. Rigante , M. Vecchi
{"title":"Butyric acid: pharmacological aspects and routes of administration","authors":"L. Spina ,&nbsp;F. Cavallaro ,&nbsp;N.I. Fardowza ,&nbsp;P. Lagoussis ,&nbsp;D. Bona ,&nbsp;C. Ciscato ,&nbsp;A. Rigante ,&nbsp;M. Vecchi","doi":"10.1016/S1594-5804(08)60004-2","DOIUrl":"10.1016/S1594-5804(08)60004-2","url":null,"abstract":"<div><p>Butyric acid is an organic acid containing 4 carbon atoms and is produced in the large intestine through fermentation by the intestinal bacterial flora of undigested sugars and dietary fibre. It is considered the most important source of energy for colonic cells; in addition, it exerts numerous anti-inflammatory effects while regulating proliferation of colonocytes and absorption of water and electrolytes. Many intestinal diseases are characterised by reduced concentrations of butyric acid in the colon and drugs that successfully prevent oxidation have been shown to be effective in the treatment of chronic inflammatory intestinal diseases.</p></div>","PeriodicalId":100375,"journal":{"name":"Digestive and Liver Disease Supplements","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2007-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1594-5804(08)60004-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79199943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 20
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信